SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 144 participants.
Also called NCT07614230
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 144 participants
- Sponsor
- Junjie Yang
- Registry
-
NCT07614230
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07614230. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2027-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
- Acronym
- SCOPE
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Condition
- Coronary Artery Disease
- Condition
- Atherosclerosis
- Intervention (Drug)
- Dapagliflozin (DAPA)
- Intervention (Other)
- Standard Care (Treatment as Usual)
- Lead sponsor
- Junjie Yang
Record details
- Record id
cardio:ct-nct07614230- Content hash
1fe44020515392eb808e4a4ddf3ce6017caf2642a4f4582429577e3abef58862